董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Scott Braunstein | 男 | Independent Director | 61 | 未披露 | 未持股 | 2025-12-31 |
| Lori Lyons Williams | 女 | Chairman of the Board | 47 | 未披露 | 未持股 | 2025-12-31 |
| Linda Kozick | 女 | Independent Director | 67 | 3.79万美元 | 未持股 | 2025-12-31 |
| Brian Wong | 男 | Director,President and Chief Executive Officer | 53 | 140.99万美元 | 未持股 | 2025-12-31 |
| Wendye Robbins | 女 | Independent Director | 64 | 未披露 | 未持股 | 2025-12-31 |
| Mary Ann Gray | 女 | Independent Director | 72 | 未披露 | 未持股 | 2025-12-31 |
| Lori Lyons Williams | 女 | Chairman of the Board | 47 | 未披露 | 未持股 | 2025-12-31 |
| Scott Braunstein | 男 | Independent Director | 61 | 未披露 | 未持股 | 2025-12-31 |
| Ashley Dombkowski | 女 | Independent Director | 54 | 未披露 | 未持股 | 2025-12-31 |
| Mary Ann Gray | 女 | Independent Director | 72 | 未披露 | 未持股 | 2025-12-31 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Dirk Brockstedt | 男 | Chief Scientific Officer | 56 | 未披露 | 未持股 | 2025-12-31 |
| Brian Wong | 男 | Director,President and Chief Executive Officer | 53 | 140.99万美元 | 未持股 | 2025-12-31 |
| Rodney Young | 男 | Chief Financial Officer | 62 | 未披露 | 未持股 | 2025-12-31 |
董事简历
中英对照 | 中文 | 英文- Scott Braunstein
-
Scott Braunstein，他于2015年6月成为董事会成员。他担任Aisling Capital（私人投资公司）的运营合伙人。他目前担任Pacira Pharmaceuticals, Inc.（NASDAQ：PCRX）的战略和企业发展高级副总裁。从2014年到2015年，他担任Everpoint Asset Management的医疗保健投资组合经理。此前从2002年到2014年，他担任JP Morgan Asset Management（JPMorgan Chase & Co. （NYSE：JPM）的部门）的各种职位。最后，他担任董事总经理、the JPM Global Healthcare Fund的高级投资组合经理、美国的制药和生物技术产业的the JPM通资产全球股票分析师。从2000年到2002年，他担任Deutsche Bank的职位。从1999年到2000年，他担任Defined Healthcare的卫生保健股票销售专家和运营副总裁。他是内科委员会认证，他担任the New York Hospital-Cornell Medical Center的职务，他获得Columbia University Medical Center的主任医师的临床助理。他获得Cornell University的学士学位以及Cornell University的the Albert Einstein College of Medicine的医学学位。
Scott Braunstein has served on our board of directors since June 2021. Dr. Braunstein currently serves as President and Chief Executive Officer and a member of the board of directors of Marinus Pharmaceuticals, positions he has held since August 2019 and September 2018 respectively. He has served as an operating partner at Aisling Capital since August 2015. From July 2015 to March 2018 Dr. Braunstein served as Chief Strategy Officer and Chief Operating Officer at Pacira Pharmaceuticals, Inc. Prior to Pacira, Dr. Braunstein served as a healthcare portfolio manager at Everpoint Asset Management from September 2014 to February 2015 and spent 12 years from February 2002 to June 2014 with J.P. Morgan Asset Management as a healthcare analyst and managing director on the U.S. equity team and as portfolio manager of the J.P. Morgan Global Healthcare Fund. Dr. Braunstein has also served on the board of directors of Trevena, Inc. since September 2018. He previously served as a board member of Constellation Pharmaceuticals from February 2019 to July 2021 Ziopharm Oncology, Inc. from September 2018 to November 2020 Esperion Therapeutics, Inc. from June 2015 to April 2020 and Protara Therapeutics, Inc. from May 2018 to July 2020. Dr. Braunstein began his career as a physician at the Summit Medical Group and as assistant clinical professor at Albert Einstein College of Medicine and Columbia University Medical Center. He received his medical degree from the Albert Einstein College of Medicine and his B.S. from Cornell University. - Scott Braunstein，他于2015年6月成为董事会成员。他担任Aisling Capital（私人投资公司）的运营合伙人。他目前担任Pacira Pharmaceuticals, Inc.（NASDAQ：PCRX）的战略和企业发展高级副总裁。从2014年到2015年，他担任Everpoint Asset Management的医疗保健投资组合经理。此前从2002年到2014年，他担任JP Morgan Asset Management（JPMorgan Chase & Co. （NYSE：JPM）的部门）的各种职位。最后，他担任董事总经理、the JPM Global Healthcare Fund的高级投资组合经理、美国的制药和生物技术产业的the JPM通资产全球股票分析师。从2000年到2002年，他担任Deutsche Bank的职位。从1999年到2000年，他担任Defined Healthcare的卫生保健股票销售专家和运营副总裁。他是内科委员会认证，他担任the New York Hospital-Cornell Medical Center的职务，他获得Columbia University Medical Center的主任医师的临床助理。他获得Cornell University的学士学位以及Cornell University的the Albert Einstein College of Medicine的医学学位。
- Scott Braunstein has served on our board of directors since June 2021. Dr. Braunstein currently serves as President and Chief Executive Officer and a member of the board of directors of Marinus Pharmaceuticals, positions he has held since August 2019 and September 2018 respectively. He has served as an operating partner at Aisling Capital since August 2015. From July 2015 to March 2018 Dr. Braunstein served as Chief Strategy Officer and Chief Operating Officer at Pacira Pharmaceuticals, Inc. Prior to Pacira, Dr. Braunstein served as a healthcare portfolio manager at Everpoint Asset Management from September 2014 to February 2015 and spent 12 years from February 2002 to June 2014 with J.P. Morgan Asset Management as a healthcare analyst and managing director on the U.S. equity team and as portfolio manager of the J.P. Morgan Global Healthcare Fund. Dr. Braunstein has also served on the board of directors of Trevena, Inc. since September 2018. He previously served as a board member of Constellation Pharmaceuticals from February 2019 to July 2021 Ziopharm Oncology, Inc. from September 2018 to November 2020 Esperion Therapeutics, Inc. from June 2015 to April 2020 and Protara Therapeutics, Inc. from May 2018 to July 2020. Dr. Braunstein began his career as a physician at the Summit Medical Group and as assistant clinical professor at Albert Einstein College of Medicine and Columbia University Medical Center. He received his medical degree from the Albert Einstein College of Medicine and his B.S. from Cornell University.
- Lori Lyons Williams
-
Lori Lyons Williams自2016年12月起担任我们的首席商务官。在加入Dermira之前，Lyons-Williams女士在Allergan plc的销售与市场营销组织中担任了15年的多个职位，最近的职位是2014年1月至2016年8月担任泌尿外科专营权的Vice President，销售和营销。此前，她曾担任Allergan&8217；s Medical Dermatology Brands的产品总监，也曾担任Aczone公司和Botox公司的营销团队的高级职务。Lyons-Williams女士的职业生涯始于担任强生公司的药品销售代表。她目前参与某些非营利组织，包括担任the National Association for Continence的董事和副主席，以及Girls，Inc.的董事。橘子郡。她持有the University of Minnesota的卡尔森管理学院的工商管理硕士学位，以及Virginia Polytechnic Institute和State University的跨学科研究学士学位。
Lori Lyons Williams has served as our Chief Commercial Officer since December 2016. Prior to joining Dermira, Ms. Lyons-Williams served 15 years in various positions within the sales and marketing organization at Allergan plc, most recently as Vice President, Sales & Marketing for the Urology franchise from January 2014 to August 2016. In previous roles within Allergan, she served as Product Director for Allergan’s medical dermatology brands and also held senior-level positions on the Aczone and Botox marketing teams. Ms. Lyons-Williams began her career as a pharmaceutical sales representative at Johnson & Johnson. She is currently involved with certain non-profit organizations, including serving as a director and Vice Chair of the National Association for Continence and as a director of Girls, Inc. Orange County. She holds an M.B.A. from the Carlson School of Management of the University of Minnesota and a B.A. in interdisciplinary studies from Virginia Polytechnic Institute and State University. - Lori Lyons Williams自2016年12月起担任我们的首席商务官。在加入Dermira之前，Lyons-Williams女士在Allergan plc的销售与市场营销组织中担任了15年的多个职位，最近的职位是2014年1月至2016年8月担任泌尿外科专营权的Vice President，销售和营销。此前，她曾担任Allergan&8217；s Medical Dermatology Brands的产品总监，也曾担任Aczone公司和Botox公司的营销团队的高级职务。Lyons-Williams女士的职业生涯始于担任强生公司的药品销售代表。她目前参与某些非营利组织，包括担任the National Association for Continence的董事和副主席，以及Girls，Inc.的董事。橘子郡。她持有the University of Minnesota的卡尔森管理学院的工商管理硕士学位，以及Virginia Polytechnic Institute和State University的跨学科研究学士学位。
- Lori Lyons Williams has served as our Chief Commercial Officer since December 2016. Prior to joining Dermira, Ms. Lyons-Williams served 15 years in various positions within the sales and marketing organization at Allergan plc, most recently as Vice President, Sales & Marketing for the Urology franchise from January 2014 to August 2016. In previous roles within Allergan, she served as Product Director for Allergan’s medical dermatology brands and also held senior-level positions on the Aczone and Botox marketing teams. Ms. Lyons-Williams began her career as a pharmaceutical sales representative at Johnson & Johnson. She is currently involved with certain non-profit organizations, including serving as a director and Vice Chair of the National Association for Continence and as a director of Girls, Inc. Orange County. She holds an M.B.A. from the Carlson School of Management of the University of Minnesota and a B.A. in interdisciplinary studies from Virginia Polytechnic Institute and State University.
- Linda Kozick
-
Linda Kozick自2016年12月以来一直担任我们的董事会成员。2011年1月至2015年7月，Kozick女士担任Bristol-Myers Squibb Co.的Opdivo和Yervoy生命周期管理的免疫肿瘤学，肿瘤产品和投资组合策略主管。Kozick女士在Chapman University获得工商管理硕士学位。Kozick女士还获得了SUNY Upstate Medical University的分子免疫学硕士学位和医疗技术学士学位。
Linda Kozick,served as Head of Immuno-Oncology, Oncology Product and Portfolio Strategy for Opdivo and Yervoy Life Cycle Management at Bristol-Myers Squibb Co. (NYSE: BMY), a pharmaceutical company. Ms. Kozick earned an M.B.A. from Chapman University. Ms. Kozick also received an M.S. in Molecular Immunology and a B.S. in Medical Technology from SUNY Upstate Medical University. - Linda Kozick自2016年12月以来一直担任我们的董事会成员。2011年1月至2015年7月，Kozick女士担任Bristol-Myers Squibb Co.的Opdivo和Yervoy生命周期管理的免疫肿瘤学，肿瘤产品和投资组合策略主管。Kozick女士在Chapman University获得工商管理硕士学位。Kozick女士还获得了SUNY Upstate Medical University的分子免疫学硕士学位和医疗技术学士学位。
- Linda Kozick,served as Head of Immuno-Oncology, Oncology Product and Portfolio Strategy for Opdivo and Yervoy Life Cycle Management at Bristol-Myers Squibb Co. (NYSE: BMY), a pharmaceutical company. Ms. Kozick earned an M.B.A. from Chapman University. Ms. Kozick also received an M.S. in Molecular Immunology and a B.S. in Medical Technology from SUNY Upstate Medical University.
- Brian Wong
-
Brian Wong自2015年8月起担任董事会成员和首席执行官，自2019年6月起担任总裁。从2009年1月到2015年8月，他担任免疫学和发现研究的Vice President，最近担任生物制药公司Five PrimeTherapeutics，Inc.的高级副总裁，研究和免疫肿瘤学主管。从2005年到2009年，他曾担任F.Hoffmann-La Roche公司（制药公司）的炎症疾病生物学领域的研究董事。Wong博士在威尔康奈尔医学院（Weill Cornell Medical College）获得医学博士学位，在洛克菲勒大学（Rockefeller University）获得免疫学博士学位。Wong博士在欧柏林学院（Oberlin College）获得化学与生物化学学士学位。
Brian Wong,has also served as a Venture Partner at The Column Group since April 2022. From January 2009 to August 2015, he served as Vice President of Immunology and Discovery Research and thereafter as Senior Vice President, Research and Head of Immuno-Oncology at Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a biopharmaceutical company. From 2005 to 2009, he served as Director of Research in the Inflammation Disease Biology Area at F. Hoffmann-La Roche Ltd. (SIX: RO, ROG; OTCQX: RHHBY), a pharmaceutical company. Dr. Wong received an M.D. from Weill Cornell Medical College and a Ph.D. in Immunology from Rockefeller University. Dr. Wong earned a B.A. in Chemistry and Biochemistry from Oberlin College. - Brian Wong自2015年8月起担任董事会成员和首席执行官，自2019年6月起担任总裁。从2009年1月到2015年8月，他担任免疫学和发现研究的Vice President，最近担任生物制药公司Five PrimeTherapeutics，Inc.的高级副总裁，研究和免疫肿瘤学主管。从2005年到2009年，他曾担任F.Hoffmann-La Roche公司（制药公司）的炎症疾病生物学领域的研究董事。Wong博士在威尔康奈尔医学院（Weill Cornell Medical College）获得医学博士学位，在洛克菲勒大学（Rockefeller University）获得免疫学博士学位。Wong博士在欧柏林学院（Oberlin College）获得化学与生物化学学士学位。
- Brian Wong,has also served as a Venture Partner at The Column Group since April 2022. From January 2009 to August 2015, he served as Vice President of Immunology and Discovery Research and thereafter as Senior Vice President, Research and Head of Immuno-Oncology at Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a biopharmaceutical company. From 2005 to 2009, he served as Director of Research in the Inflammation Disease Biology Area at F. Hoffmann-La Roche Ltd. (SIX: RO, ROG; OTCQX: RHHBY), a pharmaceutical company. Dr. Wong received an M.D. from Weill Cornell Medical College and a Ph.D. in Immunology from Rockefeller University. Dr. Wong earned a B.A. in Chemistry and Biochemistry from Oberlin College.
- Wendye Robbins
-
Wendye Robbins自2019年9月以来一直担任我们的董事会成员。她自2016年8月起担任Blade Therapeutics的总裁兼首席执行官，此前曾于2015年5月至2016年7月担任临时首席执行官。Robbins博士还曾担任公司组建和转化生物学风险投资者的独立顾问。Robbins博士自2004年以来还在斯坦福大学医学院麻醉，围手术期护理和疼痛医学系任职。Robbins博士在约翰霍普金斯大学医学院（Johns Hopkins University School of Medicine）完成麻醉学住院医师学位，在宾夕法尼亚大学医学院（University of Pennsylvania School of Medicine）完成内科实习，并在约翰霍普金斯大学医学院（John Hopkins University School of Medicine）接受疼痛医学研究金培训。Robbins博士在宾夕法尼亚医学院（Medical College of Pennsylvania）获得医学博士学位，在加州大学伯克利分校哈斯商学院（Haas School of Business）获得工商管理学士学位。
Wendye Robbins,has served as President & CEO of Incendia Therapeutics, Inc., a precision oncology company. From August 2016 to December 2022, Dr. Robbins served as President and Chief Executive Officer of Blade Therapeutics, Inc., a biopharmaceutical company, from August 2016 to December 2022 (and was Interim CEO from May 2015 to July 2016). Dr. Robbins has also been an independent consultant to venture investors and academic scientists in company formation, strategic translational biology and drug development. Dr. Robbins served on the faculty at Stanford University School of Medicine in the Department of Anesthesia, Perioperative Care, and Pain Medicine between 2004 and 2016. Dr. Robbins completed her residency in Anesthesiology at Johns Hopkins University School of Medicine, her internship in Internal Medicine at the University of Pennsylvania School of Medicine and received her fellowship training in Pain Medicine from John Hopkins University School of Medicine. Dr. Robbins received an M.D. from The Medical College of Pennsylvania and a B.S. in Business Administration from the Haas School of Business at the University of California, Berkeley. - Wendye Robbins自2019年9月以来一直担任我们的董事会成员。她自2016年8月起担任Blade Therapeutics的总裁兼首席执行官，此前曾于2015年5月至2016年7月担任临时首席执行官。Robbins博士还曾担任公司组建和转化生物学风险投资者的独立顾问。Robbins博士自2004年以来还在斯坦福大学医学院麻醉，围手术期护理和疼痛医学系任职。Robbins博士在约翰霍普金斯大学医学院（Johns Hopkins University School of Medicine）完成麻醉学住院医师学位，在宾夕法尼亚大学医学院（University of Pennsylvania School of Medicine）完成内科实习，并在约翰霍普金斯大学医学院（John Hopkins University School of Medicine）接受疼痛医学研究金培训。Robbins博士在宾夕法尼亚医学院（Medical College of Pennsylvania）获得医学博士学位，在加州大学伯克利分校哈斯商学院（Haas School of Business）获得工商管理学士学位。
- Wendye Robbins,has served as President & CEO of Incendia Therapeutics, Inc., a precision oncology company. From August 2016 to December 2022, Dr. Robbins served as President and Chief Executive Officer of Blade Therapeutics, Inc., a biopharmaceutical company, from August 2016 to December 2022 (and was Interim CEO from May 2015 to July 2016). Dr. Robbins has also been an independent consultant to venture investors and academic scientists in company formation, strategic translational biology and drug development. Dr. Robbins served on the faculty at Stanford University School of Medicine in the Department of Anesthesia, Perioperative Care, and Pain Medicine between 2004 and 2016. Dr. Robbins completed her residency in Anesthesiology at Johns Hopkins University School of Medicine, her internship in Internal Medicine at the University of Pennsylvania School of Medicine and received her fellowship training in Pain Medicine from John Hopkins University School of Medicine. Dr. Robbins received an M.D. from The Medical College of Pennsylvania and a B.S. in Business Administration from the Haas School of Business at the University of California, Berkeley.
- Mary Ann Gray
-
Mary Ann Gray，自2003年9月起担任生物技术战略规划和咨询公司Gray Strategic Advisors，LLC的总裁。此前，她曾担任Federated Kaufmann Fund（“Federated”）高级分析师和投资组合经理。在加入Federated之前，她曾在多家公司担任生物技术股票研究分析师，包括Kidder Peabody & Co.、Dillon Read & Co.和Raymond James Financial, Inc.（NYSE：RJF）。在她职业生涯的早期，她曾在制药公司先灵葆雅公司和生物技术公司NeoRX公司担任高级科学家。她目前在Compass Therapeutics Inc.（纳斯达克：CMPX）、Keros Therapeutics, Inc.（纳斯达克：KROS）和BioAtla Inc.（纳斯达克：BCAB）的董事会任职，此前曾于2019年7月至2024年3月期间在包括Palisade Bio, Inc.TERM8（纳斯达克：PALI）在内的多家公营和私营生物技术公司的董事会任职，在Sarepta Therapeutics, Inc.（纳斯达克：SRPT）于2018年12月至2022年6月期间在Senomyx，Inc.于2010年9月至ACADIA Pharmaceuticals Inc.（纳斯达克：ACAD）2005年4月至2016年6月以及德纳维制药 Corp. 2004年5月至2016年1月。Gray博士拥有南卡罗来纳大学的学士学位、佛蒙特大学的药理学博士学位，并在西北大学医学院和耶鲁大学医学院完成了博士后工作。
Mary Ann Gray,has been President of Gray Strategic Advisors, LLC, a biotechnology strategic planning and advisory firm, since September 2003. Previously, she served as Senior Analyst and Portfolio Manager of Federated Kaufmann Fund ("Federated"). Prior to Federated, she served as a biotechnology equity research analyst at multiple firms, including Kidder Peabody & Co., Dillon Read & Co. and Raymond James Financial, Inc. (NYSE: RJF). Earlier in her career, she worked as a senior scientist both at Schering Plough Corporation, a pharmaceutical company, and NeoRx Corporation, a biotechnology company. She currently serves on the boards of directors of Compass Therapeutics Inc. (Nasdaq: CMPX), Keros Therapeutics, Inc. (Nasdaq: KROS) and BioAtla Inc. (Nasdaq: BCAB), and previously served on the board of directors of many public and private biotech companies including Palisade Bio, Inc. (Nasdaq: PALI) from July 2019 to March 2024, Sarepta Therapeutics, Inc. (Nasdaq: SRPT) from December 2018 to June 2022, Senomyx, Inc. from September 2010 to November 2018, Juniper Pharmaceuticals, Inc. from March 2016 to August 2018, Galena Biopharma, Inc. from April 2016 to December 2017, TetraLogic Pharmaceuticals Corporation, ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) April 2005 to June 2016 and Dyax Corp May 2004 to January 2016. Dr. Gray holds a B.S. degree from the University of South Carolina, a Ph.D. in pharmacology from the University of Vermont and completed post-doctoral work at Northwestern University School of Medicine and at the Yale University School of Medicine. - Mary Ann Gray，自2003年9月起担任生物技术战略规划和咨询公司Gray Strategic Advisors，LLC的总裁。此前，她曾担任Federated Kaufmann Fund（“Federated”）高级分析师和投资组合经理。在加入Federated之前，她曾在多家公司担任生物技术股票研究分析师，包括Kidder Peabody & Co.、Dillon Read & Co.和Raymond James Financial, Inc.（NYSE：RJF）。在她职业生涯的早期，她曾在制药公司先灵葆雅公司和生物技术公司NeoRX公司担任高级科学家。她目前在Compass Therapeutics Inc.（纳斯达克：CMPX）、Keros Therapeutics, Inc.（纳斯达克：KROS）和BioAtla Inc.（纳斯达克：BCAB）的董事会任职，此前曾于2019年7月至2024年3月期间在包括Palisade Bio, Inc.TERM8（纳斯达克：PALI）在内的多家公营和私营生物技术公司的董事会任职，在Sarepta Therapeutics, Inc.（纳斯达克：SRPT）于2018年12月至2022年6月期间在Senomyx，Inc.于2010年9月至ACADIA Pharmaceuticals Inc.（纳斯达克：ACAD）2005年4月至2016年6月以及德纳维制药 Corp. 2004年5月至2016年1月。Gray博士拥有南卡罗来纳大学的学士学位、佛蒙特大学的药理学博士学位，并在西北大学医学院和耶鲁大学医学院完成了博士后工作。
- Mary Ann Gray,has been President of Gray Strategic Advisors, LLC, a biotechnology strategic planning and advisory firm, since September 2003. Previously, she served as Senior Analyst and Portfolio Manager of Federated Kaufmann Fund ("Federated"). Prior to Federated, she served as a biotechnology equity research analyst at multiple firms, including Kidder Peabody & Co., Dillon Read & Co. and Raymond James Financial, Inc. (NYSE: RJF). Earlier in her career, she worked as a senior scientist both at Schering Plough Corporation, a pharmaceutical company, and NeoRx Corporation, a biotechnology company. She currently serves on the boards of directors of Compass Therapeutics Inc. (Nasdaq: CMPX), Keros Therapeutics, Inc. (Nasdaq: KROS) and BioAtla Inc. (Nasdaq: BCAB), and previously served on the board of directors of many public and private biotech companies including Palisade Bio, Inc. (Nasdaq: PALI) from July 2019 to March 2024, Sarepta Therapeutics, Inc. (Nasdaq: SRPT) from December 2018 to June 2022, Senomyx, Inc. from September 2010 to November 2018, Juniper Pharmaceuticals, Inc. from March 2016 to August 2018, Galena Biopharma, Inc. from April 2016 to December 2017, TetraLogic Pharmaceuticals Corporation, ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) April 2005 to June 2016 and Dyax Corp May 2004 to January 2016. Dr. Gray holds a B.S. degree from the University of South Carolina, a Ph.D. in pharmacology from the University of Vermont and completed post-doctoral work at Northwestern University School of Medicine and at the Yale University School of Medicine.
- Lori Lyons Williams
-
Lori Lyons Williams，曾担任Abdera Therapeutics的总裁兼首席执行官和董事会成员，该公司是一家开发癌症精准放射性药物的私营生物制药公司。在加入Abdera之前，2021年4月至2022年4月，她在生物技术公司Neumora Therapeutics担任总裁兼首席运营官。此前，Lyons-Williams女士于2016年12月至2020年5月被礼来收购之前，在Dermira, Inc.（纳斯达克：DERM）担任首席商务官，该公司是一家专注于免疫学和医学皮肤病学的生物技术公司。在加入Dermira之前，Lyons-Williams女士是Allergan Ltd.（NYSE：AGN）的销售和营销副总裁。Lyons-Williams女士目前在Contineum Therapeutics董事会担任独立董事，此前曾在生物制药公司Five Prime Therapeutics, Inc.（纳斯达克：FPRX）担任独立董事，直至2021年4月被安进收购。莱昂斯-威廉姆斯女士获得了弗吉尼亚理工大学的学士学位和明尼苏达大学卡尔森管理学院的工商管理硕士学位。
Lori Lyons Williams,has served as President and Chief Executive Officer and a member of the board of directors of Abdera Therapeutics, a privately held biopharmaceutical company developing precision radiopharmaceuticals for cancer. Prior to Abdera, from April 2021 to April 2022, she was President and Chief Operating Officer at Neumora Therapeutics, a biotechnology company. Previously, Ms. Lyons-Williams served as Chief Commercial Officer at Dermira, Inc. (Nasdaq: DERM), a biotechnology company focused on immunology and medical dermatology, from December 2016 until its acquisition by Eli Lilly in May 2020. Prior to Dermira, Ms. Lyons-Williams was Vice President, Sales and Marketing at Allergan Ltd. (NYSE:AGN). Ms. Lyons-Williams currently serves as an independent director on the board of Contineum Therapeutics and previously served as an independent director for Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a biopharmaceutical company, until its acquisition by Amgen in April 2021. Ms. Lyons-Williams earned her B.A. from Virginia Tech and her M.B.A. from Carlson School of Management at the University of Minnesota. - Lori Lyons Williams，曾担任Abdera Therapeutics的总裁兼首席执行官和董事会成员，该公司是一家开发癌症精准放射性药物的私营生物制药公司。在加入Abdera之前，2021年4月至2022年4月，她在生物技术公司Neumora Therapeutics担任总裁兼首席运营官。此前，Lyons-Williams女士于2016年12月至2020年5月被礼来收购之前，在Dermira, Inc.（纳斯达克：DERM）担任首席商务官，该公司是一家专注于免疫学和医学皮肤病学的生物技术公司。在加入Dermira之前，Lyons-Williams女士是Allergan Ltd.（NYSE：AGN）的销售和营销副总裁。Lyons-Williams女士目前在Contineum Therapeutics董事会担任独立董事，此前曾在生物制药公司Five Prime Therapeutics, Inc.（纳斯达克：FPRX）担任独立董事，直至2021年4月被安进收购。莱昂斯-威廉姆斯女士获得了弗吉尼亚理工大学的学士学位和明尼苏达大学卡尔森管理学院的工商管理硕士学位。
- Lori Lyons Williams,has served as President and Chief Executive Officer and a member of the board of directors of Abdera Therapeutics, a privately held biopharmaceutical company developing precision radiopharmaceuticals for cancer. Prior to Abdera, from April 2021 to April 2022, she was President and Chief Operating Officer at Neumora Therapeutics, a biotechnology company. Previously, Ms. Lyons-Williams served as Chief Commercial Officer at Dermira, Inc. (Nasdaq: DERM), a biotechnology company focused on immunology and medical dermatology, from December 2016 until its acquisition by Eli Lilly in May 2020. Prior to Dermira, Ms. Lyons-Williams was Vice President, Sales and Marketing at Allergan Ltd. (NYSE:AGN). Ms. Lyons-Williams currently serves as an independent director on the board of Contineum Therapeutics and previously served as an independent director for Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a biopharmaceutical company, until its acquisition by Amgen in April 2021. Ms. Lyons-Williams earned her B.A. from Virginia Tech and her M.B.A. from Carlson School of Management at the University of Minnesota.
- Scott Braunstein
-
Scott Braunstein，带来了30多年来自不同生物技术和制药行业有利位置的知识和经验。自2015年起，他一直是Aisling Capital的运营合伙人。Braunstein博士此前曾于2019年8月至2025年3月期间担任被Immedica Pharma AB收购的神经病学治疗公司Marinus Pharmaceuticals, Inc.（纳斯达克：MRNS）的总裁兼首席执行官，并于2018年9月至2025年3月期间担任其董事会成员（包括2022年11月至2025年3月期间担任其主席以及2019年2月至2019年8月期间担任其执行主席）。在此之前，他曾在Pacira Pharmaceuticals，Inc.（纳斯达克：PCRX）这一专业制药公司担任高级副总裁、战略和首席运营官。在加入Pacira之前，布劳恩斯坦博士在摩根大通资产管理公司工作了12年，担任医疗保健分析师和董事总经理，并担任摩根大通全球医疗保健基金的投资组合经理。他目前在临床阶段生物制药公司atai Life Sciences N.V.（纳斯达克：ATAI）（自2024年6月起）、临床阶段CRISPR基因组编辑生物制药公司Caribou Biosciences, Inc.（纳斯达克：CRBU）（自2022年3月起）以及已签署最终协议将被礼来收购的临床阶段神经病学公司Site One Therapeutics（自2018年9月起）的董事会任职。Braunstein博士此前曾在Trevena Inc.（纳斯达克：TRVN）（2018年9月至2025年2月）、Esperion Therapeutics, Inc.（纳斯达克：ESPR）（2015年6月至2020年4月）、Ziopharm Oncology Inc.（纳斯达克：ZIOP）（2018年9月至2020年11月）、Protara Therapeutics, Inc.（f/k/a Artara Therapeutics，Inc.）（丨纳斯达克纳斯达克：TARA）（2018年5月至2020年7月）和Constellation Pharmaceuticals, Inc.（原纳斯达克：CNST）（2018年2月至2021年7月）的董事会成员中。布劳恩斯坦博士的职业生涯始于Summit Medical Group的执业医师，以及阿尔伯特·爱因斯坦医学院和哥伦比亚大学医学中心的助理临床教授。布劳恩斯坦博士获得了阿尔伯特·爱因斯坦医学院的医学博士学位和康奈尔大学的生物学BASC学位。
Scott Braunstein,brings over 30 years of knowledge and experience from diverse biotechnology and pharmaceutical industry vantage points. He has been an operating partner at Aisling Capital since 2015. Dr. Braunstein previously served as President and Chief Executive Officer of Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a neurology therapeutics company acquired by Immedica Pharma AB, from August 2019 to March 2025, and served as a member of its board of directors from September 2018 to March 2025 (including as its Chair from November 2022 to March 2025 and its Executive Chair from February 2019 to August 2019). Prior to that, he served as Senior Vice President, Strategy and Chief Operating Officer at Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), a specialty pharmaceutical company. Prior to Pacira, Dr. Braunstein spent 12 years with J.P. Morgan Asset Management as a healthcare analyst and Managing Director and as portfolio manager of the JP Morgan Global Healthcare Fund. He currently serves on the boards of directors of atai Life Sciences N.V. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company (since June 2024), Caribou Biosciences, Inc. (Nasdaq: CRBU), a clinical-stage CRISPR genome-editing biopharmaceutical company (since March 2022), and Site One Therapeutics, a clinical-stage neurology company that has signed a definitive agreement to be acquired by Eli Lilly (since September 2018). Dr. Braunstein previously served on the boards of directors of Trevena Inc. (Nasdaq: TRVN) (September 2018 to February 2025), Esperion Therapeutics, Inc. (Nasdaq: ESPR) (June 2015 to April 2020), Ziopharm Oncology Inc. (Nasdaq: ZIOP) (September 2018 to November 2020), Protara Therapeutics, Inc. (f/k/a ArTara Therapeutics, Inc.) (Nasdaq: TARA) (May 2018 to July 2020) and Constellation Pharmaceuticals, Inc. (formerly Nasdaq: CNST) (February 2018 to July 2021). Dr. Braunstein began his career as a practicing physician at the Summit Medical Group and as an assistant clinical professor at Albert Einstein College of Medicine and Columbia University Medical Center. Dr. Braunstein received an M.D. from the Albert Einstein College of Medicine and a BASc degree in biology from Cornell University. - Scott Braunstein，带来了30多年来自不同生物技术和制药行业有利位置的知识和经验。自2015年起，他一直是Aisling Capital的运营合伙人。Braunstein博士此前曾于2019年8月至2025年3月期间担任被Immedica Pharma AB收购的神经病学治疗公司Marinus Pharmaceuticals, Inc.（纳斯达克：MRNS）的总裁兼首席执行官，并于2018年9月至2025年3月期间担任其董事会成员（包括2022年11月至2025年3月期间担任其主席以及2019年2月至2019年8月期间担任其执行主席）。在此之前，他曾在Pacira Pharmaceuticals，Inc.（纳斯达克：PCRX）这一专业制药公司担任高级副总裁、战略和首席运营官。在加入Pacira之前，布劳恩斯坦博士在摩根大通资产管理公司工作了12年，担任医疗保健分析师和董事总经理，并担任摩根大通全球医疗保健基金的投资组合经理。他目前在临床阶段生物制药公司atai Life Sciences N.V.（纳斯达克：ATAI）（自2024年6月起）、临床阶段CRISPR基因组编辑生物制药公司Caribou Biosciences, Inc.（纳斯达克：CRBU）（自2022年3月起）以及已签署最终协议将被礼来收购的临床阶段神经病学公司Site One Therapeutics（自2018年9月起）的董事会任职。Braunstein博士此前曾在Trevena Inc.（纳斯达克：TRVN）（2018年9月至2025年2月）、Esperion Therapeutics, Inc.（纳斯达克：ESPR）（2015年6月至2020年4月）、Ziopharm Oncology Inc.（纳斯达克：ZIOP）（2018年9月至2020年11月）、Protara Therapeutics, Inc.（f/k/a Artara Therapeutics，Inc.）（丨纳斯达克纳斯达克：TARA）（2018年5月至2020年7月）和Constellation Pharmaceuticals, Inc.（原纳斯达克：CNST）（2018年2月至2021年7月）的董事会成员中。布劳恩斯坦博士的职业生涯始于Summit Medical Group的执业医师，以及阿尔伯特·爱因斯坦医学院和哥伦比亚大学医学中心的助理临床教授。布劳恩斯坦博士获得了阿尔伯特·爱因斯坦医学院的医学博士学位和康奈尔大学的生物学BASC学位。
- Scott Braunstein,brings over 30 years of knowledge and experience from diverse biotechnology and pharmaceutical industry vantage points. He has been an operating partner at Aisling Capital since 2015. Dr. Braunstein previously served as President and Chief Executive Officer of Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a neurology therapeutics company acquired by Immedica Pharma AB, from August 2019 to March 2025, and served as a member of its board of directors from September 2018 to March 2025 (including as its Chair from November 2022 to March 2025 and its Executive Chair from February 2019 to August 2019). Prior to that, he served as Senior Vice President, Strategy and Chief Operating Officer at Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX), a specialty pharmaceutical company. Prior to Pacira, Dr. Braunstein spent 12 years with J.P. Morgan Asset Management as a healthcare analyst and Managing Director and as portfolio manager of the JP Morgan Global Healthcare Fund. He currently serves on the boards of directors of atai Life Sciences N.V. (Nasdaq: ATAI), a clinical-stage biopharmaceutical company (since June 2024), Caribou Biosciences, Inc. (Nasdaq: CRBU), a clinical-stage CRISPR genome-editing biopharmaceutical company (since March 2022), and Site One Therapeutics, a clinical-stage neurology company that has signed a definitive agreement to be acquired by Eli Lilly (since September 2018). Dr. Braunstein previously served on the boards of directors of Trevena Inc. (Nasdaq: TRVN) (September 2018 to February 2025), Esperion Therapeutics, Inc. (Nasdaq: ESPR) (June 2015 to April 2020), Ziopharm Oncology Inc. (Nasdaq: ZIOP) (September 2018 to November 2020), Protara Therapeutics, Inc. (f/k/a ArTara Therapeutics, Inc.) (Nasdaq: TARA) (May 2018 to July 2020) and Constellation Pharmaceuticals, Inc. (formerly Nasdaq: CNST) (February 2018 to July 2021). Dr. Braunstein began his career as a practicing physician at the Summit Medical Group and as an assistant clinical professor at Albert Einstein College of Medicine and Columbia University Medical Center. Dr. Braunstein received an M.D. from the Albert Einstein College of Medicine and a BASc degree in biology from Cornell University.
- Ashley Dombkowski
-
Ashley Dombkowski，作为一名运营主管、企业家和投资者，拥有20多年的经验。自2024年11月以来，她一直担任Cellics Therapeutics，Inc.的首席执行官兼总裁，该公司是一家生物技术公司，致力于开发新型生物制剂，以解决炎症和免疫学领域未得到满足的重大医疗需求。在加入Cellics之前，她曾于2018年3月至2025年1月担任Alladapt Immunotherapeutics，Inc.的首席执行官和联合创始人，该公司是一家开发处方疗法来治疗食物过敏的生物制药公司。在此之前，Dombkowski博士是专注于早期过敏原引入的公司SpoonfulOne的首席执行官和联合创始人，以及专注于创新营养产品的公司Before Brands，Inc.的首席执行官和联合创始人。Dombkowski博士还曾担任23andMe的首席业务官兼运营副总裁。她曾在风险投资公司MPM Capital和Bay City Capital担任董事总经理15年，职业生涯早期曾担任Tiger Management L.L.C.和Dresdner RCM Global Investors的股票分析师。Dombkowski博士拥有莱斯大学的数学博士学位，并获得了韦尔斯利学院的数学学士学位。
Ashley Dombkowski,has more than 20 years of experience as an operating executive, entrepreneur and investor. She has served as Chief Executive Officer and President of Cellics Therapeutics, Inc., a biotechnology company developing novel biologics to address significant unmet medical needs in inflammation and immunology, since November 2024. Prior to Cellics, she served as Chief Executive Officer and Co-founder of Alladapt Immunotherapeutics, Inc., a biopharmaceutical company that developed prescription therapies to treat food allergy, from March 2018 to January 2025. Prior to that, Dr. Dombkowski was Chief Executive Officer and Co-founder of SpoonfulOne, a company focused on early allergen introduction, and Chief Executive Officer and Co-founder of Before Brands, Inc., a company focused on innovative nutritional products. Dr. Dombkowski also served as Chief Business Officer and Vice President of Operations for 23andMe. She spent 15 years as Managing Director at venture capital firms MPM Capital and Bay City Capital, and earlier in her career was an equity analyst for Tiger Management L.L.C. and for Dresdner RCM Global Investors. Dr. Dombkowski holds a Ph.D. in mathematics from Rice University and received her B.A. in mathematics from Wellesley College. - Ashley Dombkowski，作为一名运营主管、企业家和投资者，拥有20多年的经验。自2024年11月以来，她一直担任Cellics Therapeutics，Inc.的首席执行官兼总裁，该公司是一家生物技术公司，致力于开发新型生物制剂，以解决炎症和免疫学领域未得到满足的重大医疗需求。在加入Cellics之前，她曾于2018年3月至2025年1月担任Alladapt Immunotherapeutics，Inc.的首席执行官和联合创始人，该公司是一家开发处方疗法来治疗食物过敏的生物制药公司。在此之前，Dombkowski博士是专注于早期过敏原引入的公司SpoonfulOne的首席执行官和联合创始人，以及专注于创新营养产品的公司Before Brands，Inc.的首席执行官和联合创始人。Dombkowski博士还曾担任23andMe的首席业务官兼运营副总裁。她曾在风险投资公司MPM Capital和Bay City Capital担任董事总经理15年，职业生涯早期曾担任Tiger Management L.L.C.和Dresdner RCM Global Investors的股票分析师。Dombkowski博士拥有莱斯大学的数学博士学位，并获得了韦尔斯利学院的数学学士学位。
- Ashley Dombkowski,has more than 20 years of experience as an operating executive, entrepreneur and investor. She has served as Chief Executive Officer and President of Cellics Therapeutics, Inc., a biotechnology company developing novel biologics to address significant unmet medical needs in inflammation and immunology, since November 2024. Prior to Cellics, she served as Chief Executive Officer and Co-founder of Alladapt Immunotherapeutics, Inc., a biopharmaceutical company that developed prescription therapies to treat food allergy, from March 2018 to January 2025. Prior to that, Dr. Dombkowski was Chief Executive Officer and Co-founder of SpoonfulOne, a company focused on early allergen introduction, and Chief Executive Officer and Co-founder of Before Brands, Inc., a company focused on innovative nutritional products. Dr. Dombkowski also served as Chief Business Officer and Vice President of Operations for 23andMe. She spent 15 years as Managing Director at venture capital firms MPM Capital and Bay City Capital, and earlier in her career was an equity analyst for Tiger Management L.L.C. and for Dresdner RCM Global Investors. Dr. Dombkowski holds a Ph.D. in mathematics from Rice University and received her B.A. in mathematics from Wellesley College.
- Mary Ann Gray
-
Mary Ann Gray自2019年7月起担任董事会成员。自2018年以来，她还担任Sarepta Therapeutics, Inc.的董事会成员。从2010年到2018年，Gray博士担任Senomyx Inc.（一家致力于开发添加剂以放大食品中的某些味道和气味的生物技术公司）的董事会成员。2016年4月至2018年8月，她还担任女性健康公司Juniper Pharmaceuticals的董事会成员和审计委员会主席。2014年11月至2016年12月，她担任TetraLogic（一家上市的临床阶段生物制药公司，专注于肿瘤学和传染病）的董事会成员。从2005年到2016年，她还担任Acadia Pharmaceuticals的董事会成员，专注于CNS疗法的商业化。2001年至2016年，她担任罕见病公司Dyax Corp.的董事会成员，该公司于2016年被Shire收购。她是Gray Strategic Advisors, LLC（生物技术战略规划和咨询公司）的总裁。她拥有杰出的科学背景，完成了肿瘤生物学的药理学研究，包括治疗对心膜的影响，并开始了她在生物技术领域的职业生涯，作为一名专注于新药开发的科学家。在成为高级分析师和投资组合经理之前，她曾从事股票研究。她持有University of South Carolina的理学士学位和University of Vermont的药理学博士学位，并在Northwestern University Medical School和Yale University School of Medicine完成了博士后工作。
Mary Ann Gray has served as a member of the Board since July 2019. Since 2018 Dr. Gray has also served on the board of directors of Sarepta Therapeutics, Inc. From 2010 to 2018 Dr. Gray served as a member of the board of Senomyx Inc., a biotechnology company working toward developing additives to amplify certain flavors and smells in foods. Dr. Gray also served as a member of the board and audit committee chair of Juniper Pharmaceuticals, a women's health company, from April 2016 to August 2018. From November 2014 to December 2016 Dr. Gray served as a member of the board of TetraLogic, a publicly-held clinical-stage biopharmaceutical company focused on oncology and infectious diseases. Dr. Gray also served as a Board member of Acadia Pharmaceuticals, focused on commercialization of CNS therapies, from 2005 to 2016. Dr. Gray served as a Board member of Dyax Corp., a rare disease company acquired by Shire in 2016 from 2001 to 2016. Dr. Gray is the President of Gray Strategic Advisors, LLC, a biotechnology strategic planning and advisory firm. Dr. Gray has a distinguished scientific background, completing pharmacology research in tumor biology, including the impact of therapeutics on cardiac membranes and beginning her career in biotechnology as a scientist focused on new drug development. She subsequently worked in equities research before becoming a senior analyst and portfolio manager. Dr. Gray received a B.S. from University of South Carolina, a Ph.D. in pharmacology from the University of Vermont, and completed her post-doctoral work at Northwestern University Medical School and at the Yale University School of Medicine. - Mary Ann Gray自2019年7月起担任董事会成员。自2018年以来，她还担任Sarepta Therapeutics, Inc.的董事会成员。从2010年到2018年，Gray博士担任Senomyx Inc.（一家致力于开发添加剂以放大食品中的某些味道和气味的生物技术公司）的董事会成员。2016年4月至2018年8月，她还担任女性健康公司Juniper Pharmaceuticals的董事会成员和审计委员会主席。2014年11月至2016年12月，她担任TetraLogic（一家上市的临床阶段生物制药公司，专注于肿瘤学和传染病）的董事会成员。从2005年到2016年，她还担任Acadia Pharmaceuticals的董事会成员，专注于CNS疗法的商业化。2001年至2016年，她担任罕见病公司Dyax Corp.的董事会成员，该公司于2016年被Shire收购。她是Gray Strategic Advisors, LLC（生物技术战略规划和咨询公司）的总裁。她拥有杰出的科学背景，完成了肿瘤生物学的药理学研究，包括治疗对心膜的影响，并开始了她在生物技术领域的职业生涯，作为一名专注于新药开发的科学家。在成为高级分析师和投资组合经理之前，她曾从事股票研究。她持有University of South Carolina的理学士学位和University of Vermont的药理学博士学位，并在Northwestern University Medical School和Yale University School of Medicine完成了博士后工作。
- Mary Ann Gray has served as a member of the Board since July 2019. Since 2018 Dr. Gray has also served on the board of directors of Sarepta Therapeutics, Inc. From 2010 to 2018 Dr. Gray served as a member of the board of Senomyx Inc., a biotechnology company working toward developing additives to amplify certain flavors and smells in foods. Dr. Gray also served as a member of the board and audit committee chair of Juniper Pharmaceuticals, a women's health company, from April 2016 to August 2018. From November 2014 to December 2016 Dr. Gray served as a member of the board of TetraLogic, a publicly-held clinical-stage biopharmaceutical company focused on oncology and infectious diseases. Dr. Gray also served as a Board member of Acadia Pharmaceuticals, focused on commercialization of CNS therapies, from 2005 to 2016. Dr. Gray served as a Board member of Dyax Corp., a rare disease company acquired by Shire in 2016 from 2001 to 2016. Dr. Gray is the President of Gray Strategic Advisors, LLC, a biotechnology strategic planning and advisory firm. Dr. Gray has a distinguished scientific background, completing pharmacology research in tumor biology, including the impact of therapeutics on cardiac membranes and beginning her career in biotechnology as a scientist focused on new drug development. She subsequently worked in equities research before becoming a senior analyst and portfolio manager. Dr. Gray received a B.S. from University of South Carolina, a Ph.D. in pharmacology from the University of Vermont, and completed her post-doctoral work at Northwestern University Medical School and at the Yale University School of Medicine.
高管简历
中英对照 | 中文 | 英文- Dirk Brockstedt
Dirk Brockstedt自2019年6月起担任我们的首席科学官。在此之前，他曾于2018年1月至2019年6月担任我们的高级副总裁，生物学。自2017年10月起，他还担任梦百合投资公司ShangPharma Innovation Inc.的常驻高管。2011年9月至2017年12月，他担任研究与开发高级副总裁，最近担任生物制药公司AduroBiotech，Inc.研究与开发执行Vice President。Brockstedt博士从2007年到2009年担任Anza Therapeutics，Inc.的研究总监，从2002年到2007年担任Cerus Corporation免疫学总监，从1999年到2002年担任安万特制药公司（Aventis Pharmaceuticals，Inc.）的高级研究科学家，两家公司都是生物制药公司。在此之前，他是斯坦福医学院病理学系的博士后。Brockstedt博士在斯坦福大学（Stanford University）的基尔大学（University of Kiel）获得微生物学博士学位，并在基尔大学（University of Kiel）获得微生物学硕士学位。
Dirk Brockstedt,has also served as Executive in Residence at ShangPharma Innovation Inc., a healthcare investment company. From September 2011 to December 2017, he served as Senior Vice President of Research and Development and most recently as Executive Vice President of Research and Development at Aduro Biotech, Inc., a biopharmaceutical company. Dr. Brockstedt served as Director of Research at Anza Therapeutics, Inc. from 2007 to 2009, Director of Immunology at Cerus Corporation (Nasdaq: CERS), a biopharmaceutical company, from 2002 to 2007 and Senior Research Scientist at Aventis Pharmaceuticals, Inc. from 1999 to 2002, a pharmaceutical company. Prior to that he was a post-doctoral fellow at the Stanford School of Medicine in the Department of Pathology. Dr. Brockstedt received a Ph.D. in Microbiology from the University of Kiel (graduate work performed at Stanford University) and an M.S. in Microbiology from the University of Kiel.- Dirk Brockstedt自2019年6月起担任我们的首席科学官。在此之前，他曾于2018年1月至2019年6月担任我们的高级副总裁，生物学。自2017年10月起，他还担任梦百合投资公司ShangPharma Innovation Inc.的常驻高管。2011年9月至2017年12月，他担任研究与开发高级副总裁，最近担任生物制药公司AduroBiotech，Inc.研究与开发执行Vice President。Brockstedt博士从2007年到2009年担任Anza Therapeutics，Inc.的研究总监，从2002年到2007年担任Cerus Corporation免疫学总监，从1999年到2002年担任安万特制药公司（Aventis Pharmaceuticals，Inc.）的高级研究科学家，两家公司都是生物制药公司。在此之前，他是斯坦福医学院病理学系的博士后。Brockstedt博士在斯坦福大学（Stanford University）的基尔大学（University of Kiel）获得微生物学博士学位，并在基尔大学（University of Kiel）获得微生物学硕士学位。
- Dirk Brockstedt,has also served as Executive in Residence at ShangPharma Innovation Inc., a healthcare investment company. From September 2011 to December 2017, he served as Senior Vice President of Research and Development and most recently as Executive Vice President of Research and Development at Aduro Biotech, Inc., a biopharmaceutical company. Dr. Brockstedt served as Director of Research at Anza Therapeutics, Inc. from 2007 to 2009, Director of Immunology at Cerus Corporation (Nasdaq: CERS), a biopharmaceutical company, from 2002 to 2007 and Senior Research Scientist at Aventis Pharmaceuticals, Inc. from 1999 to 2002, a pharmaceutical company. Prior to that he was a post-doctoral fellow at the Stanford School of Medicine in the Department of Pathology. Dr. Brockstedt received a Ph.D. in Microbiology from the University of Kiel (graduate work performed at Stanford University) and an M.S. in Microbiology from the University of Kiel.
- Brian Wong
Brian Wong自2015年8月起担任董事会成员和首席执行官，自2019年6月起担任总裁。从2009年1月到2015年8月，他担任免疫学和发现研究的Vice President，最近担任生物制药公司Five PrimeTherapeutics，Inc.的高级副总裁，研究和免疫肿瘤学主管。从2005年到2009年，他曾担任F.Hoffmann-La Roche公司（制药公司）的炎症疾病生物学领域的研究董事。Wong博士在威尔康奈尔医学院（Weill Cornell Medical College）获得医学博士学位，在洛克菲勒大学（Rockefeller University）获得免疫学博士学位。Wong博士在欧柏林学院（Oberlin College）获得化学与生物化学学士学位。
Brian Wong,has also served as a Venture Partner at The Column Group since April 2022. From January 2009 to August 2015, he served as Vice President of Immunology and Discovery Research and thereafter as Senior Vice President, Research and Head of Immuno-Oncology at Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a biopharmaceutical company. From 2005 to 2009, he served as Director of Research in the Inflammation Disease Biology Area at F. Hoffmann-La Roche Ltd. (SIX: RO, ROG; OTCQX: RHHBY), a pharmaceutical company. Dr. Wong received an M.D. from Weill Cornell Medical College and a Ph.D. in Immunology from Rockefeller University. Dr. Wong earned a B.A. in Chemistry and Biochemistry from Oberlin College.- Brian Wong自2015年8月起担任董事会成员和首席执行官，自2019年6月起担任总裁。从2009年1月到2015年8月，他担任免疫学和发现研究的Vice President，最近担任生物制药公司Five PrimeTherapeutics，Inc.的高级副总裁，研究和免疫肿瘤学主管。从2005年到2009年，他曾担任F.Hoffmann-La Roche公司（制药公司）的炎症疾病生物学领域的研究董事。Wong博士在威尔康奈尔医学院（Weill Cornell Medical College）获得医学博士学位，在洛克菲勒大学（Rockefeller University）获得免疫学博士学位。Wong博士在欧柏林学院（Oberlin College）获得化学与生物化学学士学位。
- Brian Wong,has also served as a Venture Partner at The Column Group since April 2022. From January 2009 to August 2015, he served as Vice President of Immunology and Discovery Research and thereafter as Senior Vice President, Research and Head of Immuno-Oncology at Five Prime Therapeutics, Inc. (Nasdaq: FPRX), a biopharmaceutical company. From 2005 to 2009, he served as Director of Research in the Inflammation Disease Biology Area at F. Hoffmann-La Roche Ltd. (SIX: RO, ROG; OTCQX: RHHBY), a pharmaceutical company. Dr. Wong received an M.D. from Weill Cornell Medical College and a Ph.D. in Immunology from Rockefeller University. Dr. Wong earned a B.A. in Chemistry and Biochemistry from Oberlin College.
- Rodney Young
Rodney Young，于2015年6月至2019年11月在生物技术公司Cellerant Therapeutics，Inc.担任首席财务官。2014年5月至2015年2月，Young先生在生物技术公司Aimmune治疗公司担任首席财务官。2005年9月至2013年12月，他在生物技术公司StemCells，Inc.担任首席财务官以及财务和行政副总裁。Young先生在芝加哥大学Booth商学院获得金融和会计硕士学位，并在芝加哥大学获得经济学学士学位。
Rodney Young,served as Chief Financial Officer at Cellerant Therapeutics, Inc., a biotechnology company, from June 2015 to November 2019. From May 2014 to February 2015, Mr. Young served as Chief Financial Officer at Aimmune Therapeutics, Inc., a biotechnology company, and from September 2005 to December 2013 he served as Chief Financial Officer and Vice President, Finance and Administration at StemCells, Inc., a biotechnology company. Mr. Young earned an M.B.A. in Finance and Accounting from the Booth School of Business at the University of Chicago and received his B.A. in Economics from the University of Chicago.- Rodney Young，于2015年6月至2019年11月在生物技术公司Cellerant Therapeutics，Inc.担任首席财务官。2014年5月至2015年2月，Young先生在生物技术公司Aimmune治疗公司担任首席财务官。2005年9月至2013年12月，他在生物技术公司StemCells，Inc.担任首席财务官以及财务和行政副总裁。Young先生在芝加哥大学Booth商学院获得金融和会计硕士学位，并在芝加哥大学获得经济学学士学位。
- Rodney Young,served as Chief Financial Officer at Cellerant Therapeutics, Inc., a biotechnology company, from June 2015 to November 2019. From May 2014 to February 2015, Mr. Young served as Chief Financial Officer at Aimmune Therapeutics, Inc., a biotechnology company, and from September 2005 to December 2013 he served as Chief Financial Officer and Vice President, Finance and Administration at StemCells, Inc., a biotechnology company. Mr. Young earned an M.B.A. in Finance and Accounting from the Booth School of Business at the University of Chicago and received his B.A. in Economics from the University of Chicago.